Artificial Neural Networks in Diabetes Control by Fernandes, Filipe et al.
Science and Information Conference 2015 
July 28-30, 2015 | London, UK 
362 | P a g e  
www.conference.thesai.org 
Artificial Neural Networks in Diabetes Control
Filipe Fernandes 
Departamento de Informática 




Departamento de Química, Centro de Química de Évora 
Escola de Ciências e Tecnologia, Universidade de Évora 
Évora, Portugal 
hvicente@uevora.pt
António Abelha, José Machado, Paulo Novais and José Neves* 
CCTC, Universidade do Minho 
Braga, Portugal 
{abelha, jmac, pjon, jneves}@di.uminho.pt 
 
 
Abstract—Diabetes Mellitus is now a prevalent disease in both 
developed and underdeveloped countries, being a major cause of 
morbidity and mortality. Overweight/obesity and hypertension 
are potentially modifiable risk factors for diabetes mellitus, and 
persist during the course of the disease. Despite the evidence 
from large controlled trials establishing the benefit of intensive 
diabetes management in reducing microvasculars and 
macrovasculars complications, high proportions of patients 
remain poorly controlled. Poor and inadequate glycemic control 
among patients with Type 2 diabetes constitutes a major public 
health problem and a risk factor for the development of diabetes 
complications. In clinical practice, optimal glycemic control is 
difficult to obtain on a long-term basis, once the reasons for 
feebly glycemic control are complex. Therefore, this work will 
focus on the development of a diagnosis support system, in terms 
of its knowledge representation and reasoning procedures, under 
a formal framework based on Logic Programming, complemented 
with an approach to computing centred on Artificial Neural 
Networks, to evaluate the Diabetes states and the Degree-of- 
Confidence that one has on such a happening. 
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I. INTRODUCTION 
Diabetes or Diabetes Mellitus (DM), is a chronic disorder 
of glucose metabolism caused by inadequate production or use 
of insulin, a hormone produced in specialized cells (beta cells 
in the islets of Langerhans) in the pancreas, that allows for the 
use and store of glucose. The lack of insulin results in an 
inability to metabolize glucose, the capacity to store glycogen 
in the liver, and the active transport of glucose across cell 
membranes is impaired. The symptoms are elevated sugar 
levels in the blood and urine, thirst, increased urination, 
weakness, hunger and weight loss, later [1]. 
There are three main types of diabetes, namely: Type 1 
(T1D), Type 2 (T2D) and gestational. Type 1 diabetes used to 
be called juvenile-onset diabetes once it usually develops in 
children and adolescents (although can occur later in life). It is 
usually caused by an autoimmune destruction of beta cells, 
with the presence of certain antibodies in blood, leading to 
insulin deficiency [2]. Patients require lifelong insulin 
injections for survival and are at increased risk of developing 
micro vascular and macrovascular complications. T2D is 
formerly named non-insulin-dependent diabetes and it is 
characterized by hyperglycemia due to a defect in insulin 
secretion usually with a contribution from insulin resistance. 
Type 2 diabetes is due primarly to lifestyle factors, including 
obesity, lack of physical activity, poor diet, stress and 
urbanization [1]. Usually develops in adulthood, patients 
normally do not require lifelong insulin and can control blood 
glucose with diet and exercise alone, or in combination with 
oral medications. Gestational diabetes is characterized by 
hyperglycelmia of varying severity diagnosed during 
pregnancy, and commonly resolving within six weeks of 
delivery. Beyond the risk of developing T2D later in life, the 
risks to the pregnancy itself include congenital malformations, 
increased birth weight and an elevated risk of perinatal 
mortality [1]. 
In patients with type 2 diabetes mellitus, hyperglycemia is 
associated with increased morbidity and mortality for 
CardioVascular Disease (CVD) and microvascular 
complications, such as diabetic nephropathy, retinopathy, and 
neuropathy compared with those without diabetes, regardless 
of hyperglycemia per se or co-morbid conditions including 
central obesity, dyslipidaemia, arterial hypertension and insulin 
resistance [3,4]. 
As a result Diabetes is a major health problem worldwide 
with its prevalence increasing, thus becoming pandemic. 
According to the World Health Organization (WHO) more 
than 347 million people worldwide have DM [5]. Moreover, a 
recent global estimation by WHO indicated that there would be 
366 million people with DM by the year 2030 [6]. 
There are important differences between defining and 
identify an individual with diabetes and the consequent clinical 
and social implications of this diagnosis, and defining diabetes 
for epidemiological purposes. 
In the absence of a more specific biological marker to 
define diabetes, plasma glucose estimation remains the basis of 
diagnostic criteria. Other considerations, such as Hemoglobin 
1AC (HbA1c) or Cholesterol also impact on how a diagnosis 
of diabetes state should be made [7]. HbA1c can be used as a 
diagnostic test for diabetes providing that stringent quality 
